Source - LSE Regulatory
RNS Number : 6577R
Dechra Pharmaceuticals PLC
09 March 2021
 

 

 

 

9 March 2021

 

Dechra Pharmaceuticals PLC

(the Company)

Notification of Transactions by Persons Discharging Managerial Responsibilities

 

 

Dechra Pharmaceuticals PLC has been notified that on 9 March 2021 Alison Platt, Non-Executive Director, purchased 603 ordinary shares in the Company.

 

Following this acquisition, Alison Platt's beneficial interest in the Company is 1,363 shares (0.001% of the current issued share capital).

 

The Notification of Dealing Form set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Alison Platt

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volumes(s)

Price(s)

£32.905000

 

603

d)

Aggregated information

-    Aggregate volume

-    Price

-    Total

 

603

 

£32.905000

£19,841.72

e)

Date of the transaction

2021-03-09

f)

Place of the transaction

London Stock Exchange

 

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary                            

Telephone number: 01606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKCBQDBKDPNK
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.